Lonapegsomatropin

Phase 2Biologic

AAscendis Pharma Endocrinology Division A/S

Lonapegsomatropin is one of 7 biologic programs targeting Turner syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Turner SyndromeActive, not recruiting

Turner SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Turner Syndrome

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

1 2

Voxzogo

BioMarin Pharmaceutical

Phase 2

1 3

Activella

Eli Lilly

Preclinical

1 4

IC-Green

PProvepharm SAS

Preclinical

1 5

Lonapegsomatropin

AAscendis Pharma Endocrinology Division A/S

Phase 2

1 6

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Preclinical

1 7

Somatotropin

FFederico II University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Turner Syndrome

NCT05690386

Clinical

Trials by Indication[1]

Turner syndrome1 trial

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Active, not recruiting·AAscendis Pharma Endocrinology Division A/S·Phase 2·NCT05690386·48 enrolled

Adult Growth Hormone Deficiency1 trial

A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Completed·AAscendis Pharma Endocrinology Division A/S·Phase 3·NCT05171855·220 enrolled

Growth Hormone Deficiency1 trial

foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Completed·AAscendis Pharma Endocrinology Division A/S·Phase 3·NCT04615273·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lonapegsomatropin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lonapegsomatropin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lonapegsomatropin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascendis Pharma Endocrinology Division A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAscendis Pharma Endocrinology Division A/S

Lonapegsomatropin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Turner syndrome1 trial

Adult Growth Hormone Deficiency1 trial

Growth Hormone Deficiency1 trial

References

Drug Info

Quick Facts

Related News